Drug intelligence / Profile preview

RN9101

Development stage: Phase 1
Lead developer: Jiangsu Provincial People's Hospital
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

RN9101 is an experimental *in vivo* chimeric antigen receptor (CAR) T-cell therapy designed to target both CD19 and B-cell maturation antigen (BCMA). Unlike conventional *ex vivo* CAR-T therapies, which require the extraction and laboratory modification of a patient's T cells, RN9101 is engineered to produce CAR-T cells directly within the patient's body following a single intravenous infusion. This approach aims to simplify the manufacturing process and reduce the time to treatment. Developed by The First Affiliated Hospital with Nanjing Medical University, RN9101 is currently being evaluated in Phase 1 clinical trials for the treatment of relapsed or refractory multiple myeloma.

Beyond the preview

Go deeper on RN9101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RN9101.

Explore the full profile